Celalettin Ustun to Remission Induction
This is a "connection" page, showing publications Celalettin Ustun has written about Remission Induction.
Connection Strength
0.077
-
Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Adv. 2022 01 08; 6(3):828-847.
Score: 0.049
-
Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant. 2014 Feb; 20(2):202-8.
Score: 0.028